780 related articles for article (PubMed ID: 19379170)
1. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
[TBL] [Abstract][Full Text] [Related]
2. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
[TBL] [Abstract][Full Text] [Related]
3. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
Avbersek-Luznik I; Balon BP; Rus I; Marc J
Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
[TBL] [Abstract][Full Text] [Related]
4. Mineral-bone metabolism markers in young hemodialysis patients.
Osorio A; Ortega E; Torres JM; Sanchez P; Ruiz-Requena E
Clin Biochem; 2011 Dec; 44(17-18):1425-8. PubMed ID: 21933667
[TBL] [Abstract][Full Text] [Related]
5. Increased levels of osteoprotegerin in hemodialysis patients.
Avbersek-Luznik I; Malesic I; Rus I; Marc J
Clin Chem Lab Med; 2002 Oct; 40(10):1019-23. PubMed ID: 12476941
[TBL] [Abstract][Full Text] [Related]
6. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease.
Siomou E; Challa A; Printza N; Giapros V; Petropoulou F; Mitsioni A; Papachristou F; Stefanidis CJ
Pediatr Nephrol; 2011 Jul; 26(7):1105-14. PubMed ID: 21479768
[TBL] [Abstract][Full Text] [Related]
7. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
Shaarawy M; Fathy SA; Mehany NL; Hindy OW
Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
[TBL] [Abstract][Full Text] [Related]
8. Bone cytokines and renal osteodystrophy in peritoneal dialysis patients.
Mesquita M; Wittersheim E; Demulder A; Dratwa M; Bergmann P
Adv Perit Dial; 2005; 21():181-4. PubMed ID: 16686314
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between coronary and abdominal calcification score, serum osteoprotegerin (OPG), and serum tartrate-resistant acid phosphatase (TRACP) -5b in pre-dialysis CKD patients].
Shiota J; Izumi N; Kasahara H; Tagawa H; Chiba T; Nihei H
Nihon Jinzo Gakkai Shi; 2010; 52(8):1022-8. PubMed ID: 21254698
[TBL] [Abstract][Full Text] [Related]
10. [Tartrate-resistant acid phosphatase--TRAP 5b--as a novel marker of bone resorption in patients with irreversible renal failure treated with dialysis].
Nowak Z; Konieczna M; Wańkowicz Z
Pol Merkur Lekarski; 2004 Aug; 17(98):138-41. PubMed ID: 15603322
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients.
Haas M; Leko-Mohr Z; Roschger P; Kletzmayr J; Schwarz C; Domenig C; Zsontsich T; Klaushofer K; Delling G; Oberbauer R
Am J Kidney Dis; 2002 Mar; 39(3):580-6. PubMed ID: 11877577
[TBL] [Abstract][Full Text] [Related]
12. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
[TBL] [Abstract][Full Text] [Related]
13. Serum markers of bone turnover in dialyzed patients grouped by level of intact parathyroid hormone.
Grzegorzewska AE; Mlot-Michalska M
Adv Perit Dial; 2006; 22():203-6. PubMed ID: 16983970
[TBL] [Abstract][Full Text] [Related]
14. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
15. Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis.
Ambroszkiewicz J; Sands D; Gajewska J; Chelchowska M; Laskowska-Klita T
Adv Med Sci; 2013; 58(2):338-43. PubMed ID: 24277958
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin and bone mineral density in hemodiafiltration patients.
Crisafulli A; Romeo A; Floccari F; Aloisi E; Atteritano M; Cincotta M; Aloisi C; Pizzoleo MA; Ruello A; Artemisia A; Valenti A; Frisina N; Teti D; Buemi M
Ren Fail; 2005; 27(5):531-9. PubMed ID: 16152990
[TBL] [Abstract][Full Text] [Related]
17. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
18. Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients.
Grzegorzewska AE; Mlot M
Adv Perit Dial; 2005; 21():188-93. PubMed ID: 16686316
[TBL] [Abstract][Full Text] [Related]
19. Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients.
Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Stathakis CP; Diamanti-Kandarakis E; Dimitroulis D; Perrea DN
J Bone Miner Metab; 2008; 26(1):66-72. PubMed ID: 18095066
[TBL] [Abstract][Full Text] [Related]
20. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
Evans CE; Mylchreest S; Andrew JG
BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
